ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression

Authors

Institutions

Publication Details

Journal
JAMA Psychiatry
Published
2025-09-10
DOI
https://doi.org/10.1001/jamapsychiatry.2025.2416
Citations
5
Primary Topic
Pharmaceutical studies and practices
Type
article
Field-Weighted Citation Impact
17.47
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression

Matthew A. Spear, Larry Alphs, Shaohui Wu, G. Wang et al.
5 citations
JAMA Psychiatry
Pharmaceutical studies and practices
17.47
article

ANK3 as a Novel Genetic Biomarker for Liafensine in Treatment-Resistant Depression

Matthew A. Spear, Larry Alphs, Shaohui Wu, G. Wang, Charles B. Nemeroff, Ashok R. Patel, Shikai Wang, Anning Li, Xiaoxiong Lu, Crystal Chen, Holly Huang, Mario Aguado, Julie Doostzadeh, Wen Luo, Zhiqiang Wang
article en
5 citations

Abstract

No abstract available for this paper.
JAMA PsychiatryVol. 82(12)
Capital Medical University (CN), Beijing Anding Hospital (CN), Jiangxi Mental Health Center (CN), RG Biopharma (United States) (US), Third People's Hospital of Huzhou (CN), Advanced Memory Research Institute of New Jersey (US), School of Clinical Research (US), The University of Texas at Austin (US)
Openalex Percentile: Top 1%
Pharmaceutical studies and practices
17.47
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.